Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)
Clinical trial NCT05876364 · UNKNOWN
Trial details
- NCT number
- NCT05876364
- Sponsor
- Quratis Inc.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-19
- Primary completion
- 2022-06-13
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.